English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 12 September 2023, 19:05 JST
Share:
    

Source: Eisai
Eisai Establishes Theoria Technologies Co., Ltd., A New Digital Business Company To Build A Dementia Ecosystem

TOKYO, Sept 12, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has established a digital business company Theoria technologies Co., Ltd. ("Theoria technologies") which will accelerate the development of a dementia ecosystem. Theoria technologies is a wholly owned subsidiary of Eisai.

With the aim of relieving the anxieties of people with dementia and their families and addressing social issues, Eisai is not only creating therapeutic drugs, but also working to build a dementia ecosystem through the development of digital solutions and collaboration with other industries. Theoria technologies will serve as the core of a highly transparent and neutral dementia platform, and the foundation for the development of an ecosystem to empower the people with dementia, regardless of the type or stage of the disease, to "live their fullest lives".

Theoria technologies will accelerate decision-making and strengthen the hiring and training of digital talent under an organizational structure optimized for digital business, and will utilize clinical study data that Eisai has accumulated over many years as well as cohort study data, Personal Health Records (PHR), and other data to develop various prediction algorithms, create digital solutions and provide data. Theoria technologies will commence business activities in April 2024, with the aim of providing services for a risk prediction algorithm for early detection of mild cognitive impairment (MCI) and dementia in FY2024. In addition, together with Eisai, Theoria technologies will develop and provide Sasaeru, an application that helps facilitate communication between people with dementia, doctors, and caregivers by recording Activities of Daily Living (ADL) of the people with dementia. Furthermore, Theoria technologies will promote the development of digital services by strengthening collaboration with other companies.

Eisai is aiming to create social impact by realizing a Dementia Inclusive Society where people with dementia and the people in the daily living domain can live their lives how they would like, through the development of an ecosystem.

For more information, visit www.eisai.com/news/2023/news202356.html.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Wednesday, 15 January 2025, 10:03 JST
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
2025年1月14日 10時00分 JST
エーザイとバイオジェン・インク、早期アルツハイマー病治療剤「レケンビ(R)」の皮下注射製剤維持投与に関する 生物製剤承認申請を米国FDAが受理
2025年1月7日 9時00分 JST
金沢大とエーザイ、レカネマブがアルツハイマー病の病態進行を抑制するメカニズムの一端を解明
Tuesday, 7 January 2025, 9:14 JST
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
Monday, 23 December 2024, 17:22 JST
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
More news >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575